Exagen Inc.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 14:49

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.
Exagen Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting") on June 10, 2025. At the Annual Meeting, the Company's stockholders voted on four proposals, as described below. Each of the proposals was described in detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 30, 2025 (the "Proxy Statement"). The vote totals noted below are final voting results from the Annual Meeting.
Proposal 1
The Company's stockholders elected the following two Class III directors for a three-year term of office expiring at the Company's 2028 annual meeting of stockholders and until their successors are duly elected and qualified or until such director's earlier death, resignation or removal.
Name
Votes For
Votes Withheld
Broker Non-Votes
John Aballi
8,593,115
32,626
2,997,490
Bruce C. Robertson, Ph.D.
5,656,283
2,969,458
2,997,490
Proposal 2
The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
Votes For
Votes Against
Abstentions
Broker Non-Votes
11,532,748
74,611
15,872
__
Proposal 3
The Company's stockholders approved, by an advisory vote, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.
Votes For
Votes Against
Abstentions
Broker Non-Votes
8,599,414
16,752
9,575
2,997,490
Proposal 4
The Company's stockholders approved, by an advisory vote, the frequency of holding future advisory votes to approve the compensation of the Company's named executive officers.
1 Year
2 Years
3 Years
Abstentions
Broker Non-Votes
8,376,265 86,357 155,681 7,438 2,997,490
In light of these results, and consistent with the recommendation of the Company's board of directors to stockholders in the Proxy Statement, the Company's policy will be to hold an advisory vote on executive compensation every year until the next required vote by stockholders on the frequency of future advisory votes on named executive officer compensation.
Exagen Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 11, 2025 at 20:50 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io